NL-OMON55750已完成3 期
A multi-center, open-label, uncontrolled, single-arm, extension study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease - OLE
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Signed and dated ICF prior to any study-mandated procedure;
- •2. Subject completed the 6-month, double-blind treatment period in study ID
排除标准
- •1. Pregnant / planning to become pregnant or lactating subject;
- •2. Subject considered to be at high risk of developing clinical signs of organ
- •involvement within the time period of the study, as per investigator judgment;
- •3. Any known factor or disease that might interfere with treatment compliance,
- •study conduct or interpretation of the results as per investigator judgment.,
- •In addition, the subject must not be enrolled in study ID-069A302 if at any
- •time during study ID-069A301, one of the following criteria was met:
- •4. Subject*s eGFR per the Chronic Kidney Disease Epidemiology Collaboration
- •creatinine equation < 15 mL/min/1.73 m2;
- •5. Subject experienced an event of acute kidney injury Common Terminology
- •Criteria for Adverse Event (CTCAE) grade 2 or above;
- •6. Subject experienced an event of stroke CTCAE grade 3 or above;
- •7. Subject experienced an event of heart failure leading to in-patient
- •hospitalization or prolongation of ongoing hospitalization.
研究者
相似试验
进行中（未招募）
1 期
A study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry diseaseMedDRA version: 20.0Level: SOCClassification code 10010331Term: Congenital, familial and genetic disordersSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 24.1Level: PTClassification code 10016016Term: Fabry's diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersFabry diseaseEUCTR2018-002210-12-DEIdorsia Pharmaceuticals Ltd107
进行中（未招募）
1 期
A study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry diseaseMedDRA version: 20.0Level: SOCClassification code 10010331Term: Congenital, familial and genetic disordersSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 24.1Level: PTClassification code 10016016Term: Fabry's diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersFabry diseaseEUCTR2018-002210-12-NLIdorsia Pharmaceuticals Ltd108
进行中（未招募）
1 期
A study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry diseaseFabry diseaseEUCTR2018-002210-12-FRIdorsia Pharmaceuticals Ltd108
进行中（未招募）
1 期
A study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry diseaseMedDRA version: 20.0Level: SOCClassification code 10010331Term: Congenital, familial and genetic disordersSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 24.1Level: PTClassification code 10016016Term: Fabry's diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersFabry diseaseEUCTR2018-002210-12-BEIdorsia Pharmaceuticals Ltd107
进行中（未招募）
1 期
A study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry diseaseMedDRA version: 20.0Level: SOCClassification code 10010331Term: Congenital, familial and genetic disordersSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 24.1Level: PTClassification code 10016016Term: Fabry's diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersFabry diseaseEUCTR2018-002210-12-ATIdorsia Pharmaceuticals Ltd107